A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, data, interpretation, outcome, statin | 1 Comment »
Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, dose, Jevtana, lower, mCRPC | Leave a comment »
In another presentation from the ESMO meeting in Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: cabazitaxel, chemotherapy, choice, docetaxel, preference, taxane | 2 Comments »
The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, docetaxel, dosing, Jevtana, outcome, Taxotere | 3 Comments »
In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AFFINITY, cabazitaxel, custirsen, outcome, Phase III, trial | Leave a comment »
According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, England, NICE | Leave a comment »
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, chemotherapy, CRPC | 10 Comments »
A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cabazitaxel, outcome, risk, sequencing, Treatment | Leave a comment »
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, aflibercept, ARN-509, cabazitaxel, cediranib, dasatinib, enzalutamide, radium-223, sipuleucel-T | 6 Comments »
